Drug Profile
Research programme: effervescent formulation therapeutics - EffRx/Kadmon
Latest Information Update: 02 Jun 2023
Price :
$50
*
At a glance
- Originator Kadmon Corporation
- Developer EffRx; Kadmon Corporation
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatolenticular degeneration; Unspecified
Most Recent Events
- 29 May 2023 EffRx has been acquired by Abiogen Pharma
- 28 Jul 2018 No recent reports of development identified for research development in Undefined in Switzerland
- 28 Jul 2018 No recent reports of development identified for research development in Undefined in USA